Molecular Targets
Annunziata, Christina M. (et al.)
Preclinical Screening for New Anticancer Agents
Burger, Angelika M. (et al.)
Natural Product Screening
McKee, Tawnya C. (et al.)
Defining the Starting Dose: Should It Be mg/kg, mg/m
Gao, Bo (et al.)
Phase 0 Trials in Oncology
Kummar, Shivaani (et al.)
Phase I Trials in Oncology: Design and Endpoints
Glen, Hilary (et al.)
Quantitative Analytical Methods: Development and Clinical Considerations
Gardner, Erin R.
Validation and Control of Bioanalytical Methods
Karnes, H. Thomas (et al.)
Anticancer Clinical Pharmacology Overview
Dandamudi, Uday B. (et al.)
Pharmacokinetic Modeling
Li, Jing (et al.)
Pharmacometrics
Brar, Satjit S. (et al.)
Pharmacodynamic Modeling
Bauer, Kenneth S. (et al.)
Protein Binding
Sparreboom, Alex (et al.)
Metabolism (Non-CYP Enzymes)
Jamieson, David (et al.)
Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms
Patel, Jai N. (et al.)
Cytochrome P450
Ando, Yuichi
Polymorphisms in Genes of Drug Targets and Metabolism
Bohanes, Pierre (et al.)
DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance
Reed, Eddie (et al.)
Drug Interactions
Rivory, Laurent P.
ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition
Massey, Paul R. (et al.)
Solute Carriers
Ho, Richard H. (et al.)
High-Throughput Platforms in Drug Metabolism and Transport Pharmacogenetics
English, Bevin C. (et al.)
Intrathecal Administration
Kilburn, Lindsay B. (et al.)
Microdialysis
Combest, Austin J. (et al.)
Regional Drug Delivery for Inoperable Pulmonary Malignancies
Schrump, David S.
Blood-Brain Barrier and CNS Malignancy
Balmanoukian, Ani (et al.)
Radiation and Altering Clinical Pharmacology
Smart, DeeDee (et al.)
Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment
Madan, Ravi A. (et al.)
Recombinant Immunotoxins
Kreitman, Robert J.
Monoclonal Antibodies
Bai, Shuang (et al.)
Clinical Pharmacology in Pediatrics
Tagen, Michael (et al.)
Clinical Pharmacology in the Older Adult
Slattum, Patricia W. (et al.)
Organ Dysfunction Trials: Background, Historical Barriers, Progress in Overcoming Barriers, and Suggestions for Future Trials
Kummar, Shivaani (et al.)
Drug Formulations: How these Affects Anticancer Drug
Lagas, Jurjen S. (et al.)
Nanotechnology in Cancer
Janát-Amsbury, Margit M. (et al.)
Imaging in Drug Development
Kurdziel, Karen A. (et al.)
Exposure-Response Relationships of Anticancer Agents: Application in Drug Development and Drug Label
Rahman, Atiqur
The Role of Phase III Trials in Modern Drug Development
Murphy, Janet E. (et al.)
Clinical Trial Designs for Approval of New Anticancer Agents
Chadha, Manpreet K. (et al.)
Clinical Pharmacogenetics
Sachidanandam, Kamakshi (et al.)
About the Author: Dr. Michelle Rudek received her BS in Pharmacy from the University of Pittsburgh and her dual Pharm.D., Ph.D. from Virginia Commonwealth University in a joint clinical pharmacology/oncology program with the National Cancer Institute. Dr. Rudek joined Johns Hopkins University in 2001 and is currently an Associate Professor of Oncology and Director of the Analytical Pharmacology Core Laboratory. Her research program is focused on clinical pharmacology with a focus on early phase drug development and special populations including AIDS malignancy and organ dysfunction.
Dr. Cindy H. Chau received her BS in Molecular, Cell, and Developmental Biology from UCLA and her Pharm.D. and Ph.D. (in Molecular Pharmacology and Toxicology) dual degrees from the University of Southern California School of Pharmacy as a National Institutes of Health (NIH) predoctoral fellow. She was the recipient of the NIH National Research Service Award. Dr. Chau completed a postdoctoral fellowship at the NIH, joining the National Cancer Institute in 2004 and is currently a research scientist within the Medical Oncology Branch, Center for Cancer Research.
Dr. William Douglas Figg received his B.S. (Hon) from Georgetown College, his B.S. in Pharmacy from Samford University and his Pharm.D. from Auburn University. He completed his clinical pharmacy internship at the University of Alabama at Birmingham Hospital and his fellowship in drug development at the University of North Carolina-Chapel Hill. Dr. Figg also received an M.B.A. degree from a combined program at Columbia University and London Business School. He joined the Medical Oncology Branch, National Cancer Institute, National Institutes of Health in 1992. He has patented more than 80 new anticancer agents and four pharmacogenetic tests.
Dr. Howard McLeod is Fred Eshelman Distinguished Professor and Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill. Dr. McLeod holds appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Comprehensive Cancer Center. Dr McLeod is chair of the NHGRI eMERGE network external scientific panel and is a member of the FDA committee on Clinical Pharmacology. He is a member of the NIH NHGRI Advisory Council. Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the NCI clinical trials cooperative group CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world.
